File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A meta-analysis on intravenous magnesium sulphate for treating acute asthma

TitleA meta-analysis on intravenous magnesium sulphate for treating acute asthma
Authors
Issue Date2005
PublisherB M J Publishing Group. The Journal's web site is located at http://www.archdischild.com/
Citation
Archives of Disease in Childhood, 2005, v. 90 n. 1, p. 74-77 How to Cite?
Abstract
AIM: To evaluate the effectiveness of intravenous magnesium sulphate in the treatment of acute asthmatic attacks in children by meta-analysis. METHODS: A systematic and comprehensive search of the literature was performed to identify controlled clinical trials of magnesium sulphate in paediatric acute asthma which evaluated outcomes of hospitalisation or short term pulmonary function tests or symptom scores. Unpublished data were searched by personal contacts with authors and specialists. Two reviewers independently assessed trial qualities and synthesised data. Heterogeneity among studies was evaluated by the Cochrane Q test. Outcome data were pooled by random or fixed effect models depending on presence or absence of heterogeneity. RESULTS: Five randomised placebo controlled trials involving a total of 182 patients were identified. They compared intravenous magnesium sulphate to placebo in treating paediatric patients with moderate to severe asthmatic attacks in the emergency department, with co-therapies of inhaled beta2 agonists and systemic steroids. The studies were of high quality with results judged to be valid. Four studies showed that magnesium sulphate was effective, while one study found it ineffective. There was no significant heterogeneity in the primary outcome of hospitalisation. In the fixed effect model, magnesium sulphate is effective in preventing hospitalisation (OR 0.290, 95% CI 0.143 to 0.589). The number needed to treat is 4 (95% CI 3 to 8). Secondary outcomes of short term pulmonary function tests and clinical symptom scores also showed significant improvement. CONCLUSION: Intravenous magnesium sulphate probably provides additional benefit in moderate to severe acute asthma in children treated with bronchodilators and steroids.
Persistent Identifierhttp://hdl.handle.net/10722/45209
ISSN
2013 Impact Factor: 2.905
PubMed Central ID
ISI Accession Number ID

 

Author Affiliations
  1. The University of Hong Kong
  2. Hong Kong Baptist University
DC FieldValueLanguage
dc.contributor.authorCheuk, DKLen_HK
dc.contributor.authorChau, TCHen_HK
dc.contributor.authorLee, SLen_HK
dc.date.accessioned2007-10-30T06:19:56Z-
dc.date.available2007-10-30T06:19:56Z-
dc.date.issued2005en_HK
dc.identifier.citationArchives of Disease in Childhood, 2005, v. 90 n. 1, p. 74-77en_HK
dc.identifier.issn0003-9888en_HK
dc.identifier.urihttp://hdl.handle.net/10722/45209-
dc.description.abstractAIM: To evaluate the effectiveness of intravenous magnesium sulphate in the treatment of acute asthmatic attacks in children by meta-analysis. METHODS: A systematic and comprehensive search of the literature was performed to identify controlled clinical trials of magnesium sulphate in paediatric acute asthma which evaluated outcomes of hospitalisation or short term pulmonary function tests or symptom scores. Unpublished data were searched by personal contacts with authors and specialists. Two reviewers independently assessed trial qualities and synthesised data. Heterogeneity among studies was evaluated by the Cochrane Q test. Outcome data were pooled by random or fixed effect models depending on presence or absence of heterogeneity. RESULTS: Five randomised placebo controlled trials involving a total of 182 patients were identified. They compared intravenous magnesium sulphate to placebo in treating paediatric patients with moderate to severe asthmatic attacks in the emergency department, with co-therapies of inhaled beta2 agonists and systemic steroids. The studies were of high quality with results judged to be valid. Four studies showed that magnesium sulphate was effective, while one study found it ineffective. There was no significant heterogeneity in the primary outcome of hospitalisation. In the fixed effect model, magnesium sulphate is effective in preventing hospitalisation (OR 0.290, 95% CI 0.143 to 0.589). The number needed to treat is 4 (95% CI 3 to 8). Secondary outcomes of short term pulmonary function tests and clinical symptom scores also showed significant improvement. CONCLUSION: Intravenous magnesium sulphate probably provides additional benefit in moderate to severe acute asthma in children treated with bronchodilators and steroids.en_HK
dc.format.extent166274 bytes-
dc.format.extent1778 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherB M J Publishing Group. The Journal's web site is located at http://www.archdischild.com/en_HK
dc.rightsArchives of Disease in Childhood. Copyright © B M J Publishing Group.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAnti-Asthmatic-Agents-administration-and-dosageen_HK
dc.subject.meshAsthma-drug-therapyen_HK
dc.subject.meshMagnesium-Sulfate-administration-and-dosageen_HK
dc.titleA meta-analysis on intravenous magnesium sulphate for treating acute asthmaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0003-9888&volume=90&issue=1&spage=74&epage=77&date=2005&atitle=A+meta-analysis+on+intravenous+magnesium+sulphate+for+treating+acute+asthmaen_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1136/adc.2004.050005en_HK
dc.identifier.pmid15613519en_HK
dc.identifier.pmcidPMC1720072-
dc.identifier.scopuseid_2-s2.0-11144229833-
dc.identifier.isiWOS:000225865900019-
dc.identifier.citeulike3401720-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats